ROCKVILLE, Md., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the publication of an article that reported new safety, immunogenicity and cross-reactivity results from a Phase I/IIa clinical study of the company’s H5N1 influenza virus-like particle (VLP) vaccine candidate that was conducted in 2008. According to the report in the current issue of Journal of Virology, Novavax’s VLP-based vaccine targeted against a highly pathogenic avian H5N1 influenza virus was well-tolerated, produced no vaccine-related serious adverse events and induced neutralizing antibodies that were cross-reactive with different avian A/H5N1 influenza viruses. This is the first report of a unadjuvanted vaccine inducing cross-reactive neutralizing antibodies against multiple clades of H5N1 influenza virus.
